Ticker | Value | Shares | Price | Security | Type | Insider | Title | Return | Flags | Date |
|---|---|---|---|---|---|---|---|---|---|---|
| No transactions found | ||||||||||
Mark James Litton currently holds 750,000 shares of Athira Pharma, Inc. (ATHA), valued at approximately $0. This represents their equity stake as Executive.
Based on SEC Form 4 filings, Mark James Litton has been a net seller of ATHA stock. They have purchased $0 and sold $5.6M worth of shares.
Mark James Litton's most recent insider trade was on Apr 9, 2026, when they sold 750,000 shares at $0.00 per share.
Mark James Litton serves as Executive at Athira Pharma, Inc. (ATHA). They have executed 74 insider transactions totaling $5.6M over their tenure at the company.
Mark James Litton holds the position of Executive at Athira Pharma, Inc., where they are responsible for executive-level decision-making and strategic oversight. They have been associated with the company for 12 years and currently hold a stake valued at $0.
Mark James Litton has shown a selling trading pattern, with $0 in total purchases and $5.6M in total sales across all transactions. Their most recent activity indicates a tendency to reduce their position.
The largest transaction by Mark James Litton was on Jun 1, 2018, when they sold $323.8K worth of ALDR shares. This transaction involved 18,253 shares at $17.74 per share.
Mark James Litton currently owns 750,000 shares of Athira Pharma, Inc. (ATHA), with an estimated value of $0. This stake represents their equity holdings accumulated through purchases, awards, and option exercises.
All of Mark James Litton's SEC Form 4 insider trading filings are tracked on this page. Each transaction links directly to the official SEC EDGAR filing. Mark James Litton has 74 Form 4 filings on record as an insider at Athira Pharma, Inc..
Set alerts for Mark James Litton and 40,000+ other insiders.